BCM
COLL icon

Bayesian Capital Management’s Collegium Pharmaceutical COLL Stock Holding History

Bayesian Capital Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,853
Closed -$275K – 202
2025
Q3 		$275K Buy
+7,853
New +$273K 0.06% 397
2024
Q4 		– Sell
-8,391
Closed -$324K – 730
2024
Q3 		$324K Buy
+8,391
New +$299K 0.04% 458
2020
Q2 		– Sell
-14,300
Closed -$234K – 559
2020
Q1 		$234K Buy
+14,300
New +$295K 0.05% 538

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bayesian Capital Management's COLL Position: Q4 2025 in Review

Bayesian Capital Management sold out of Collegium Pharmaceutical (COLL) in Q4 2025, closing a stake of 7,853 shares — an estimated $275K sold.

Bayesian Capital Management first reported a position in COLL in Q1 2020 and held it in 3 quarters. The position peaked at $324K in Q3 2024. 278 funds tracked by Wall St. Rank hold COLL as of Q4 2025.

  • Bayesian Capital Management reported no remaining Collegium Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 7,853 Collegium Pharmaceutical shares in Q4 2025, an estimated $275K.
  • Bayesian Capital Management first reported a position in Collegium Pharmaceutical in Q1 2020 and held it in 3 quarters.
  • Bayesian Capital Management's Collegium Pharmaceutical position peaked at $324K in Q3 2024.
  • 278 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.